KRAS and vascular neoplasm: Recently published reports have shown that the hyperactive RAS/MAPK signaling is implicated in other vascular tumors and malformations57 and some authors successfully modeled mouse vascular anomalies associated with KRAS-G12D/V activating mutations58–60.